Study: For women over 60, muscle strength matters
You don’t need to look like a bodybuilder, but for healthy aging, maintaining muscle strength is likely just as important as getting enough aerobic activity. That’s according to… read more.
You don’t need to look like a bodybuilder, but for healthy aging, maintaining muscle strength is likely just as important as getting enough aerobic activity. That’s according to… read more.
Intermittent fasting is unlikely to lead to greater weight loss in overweight or obese adults than traditional dietary advice or doing nothing, a new Cochrane review finds. Obesity… read more.
Citius Oncology Inc., the oncology-focused subsidiary of Citius Pharmaceuticals Inc. announced that it has entered into an exclusive distribution agreement with Uniphar , a leading international healthcare services… read more.
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting FRAMINGHAM, Mass. & SALISBURY, England–(BUSINESS WIRE)–Feb. 12, 2026– KalVista Pharmaceuticals, Inc…. read more.
American women now have the option of screening for cervical cancer at home, using newly approved self-collection tools. While experts hope this will increase uptake in the under-screened population, a… read more.
More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control, according to the Joint United Nations Programme on HIV/AIDS… read more.
Key data from Merck’s portfolio and pipeline to be presented at the 2026 ASCO GU Cancers Symposium: First-time data from the Phase 3 KEYNOTE-B15/EV-304 trial evaluating KEYTRUDA, Merck’s… read more.
Biofrontera Inc. announced that the FDA has completed its filing review and accepted filing of the Company’s supplemental New Drug Application (sNDA) for Ameluz (aminolevulinic acid hydrochloride) topical… read more.
Ono Pharmaceutical Co., Ltd. announced that the FDA has accepted for filing the New Drug Application (NDA) under the accelerated approval pathway for tirabrutinib, a highly selective irreversible,… read more.
In the U.S., one in eight women will get breast cancer in their lifetime, and about half of them will have mastectomies. Many of those women opt to… read more.
Pfizer Inc. announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating Braftovi (encorafenib) in combination with cetuximab (Erbitux) and FOLFIRI (fluorouracil,… read more.
HRT via skin is best treatment for low bone density in women whose periods have stopped due to anorexia or exercise, says study. Hormone replacement therapy applied via… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.